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Summary: In Malawian pregnant women with placental malaria, the presence of parasites with the 
SP-resistance allele dhps A581G was associated with lower birthweights, but antenatal SP receipt did 
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Background. Sulfadoxine-pyrimethamine (SP) is used as intermittent preventive therapy in 
pregnancy (IPTp) for malaria in sub-Saharan Africa. The resistance marker dhps A581G has been 
associated with reduced IPTp-SP efficacy and enhanced morbidity in SP-recipients. 
 
Methods. We measured SP-resistance allele frequencies in Malawian women participating in a trial 
(www.isrctn.com/ISRCTN69800930) comparing IPTp with SP against intermittent screening by rapid 
diagnostic tests (ISTp). We genotyped PCR-detected parasites using deep sequencing of SP-
resistance alleles. 
 
Results. Among 125 placental infections, A581G-bearing parasites were associated with reduced 
birthweight (mean difference[MD]:252g, 95% CI:46,457, p=0.017). Relative to ISTp, IPTp-SP was 
associated with higher birthweights in women with wildtype parasites (MD:116g, 95% CI:-40,272; 
p=0.142) and lower birthweights in women with A581G-bearing parasites (MD:192g, 95% CI:-
264,648; p=0.385) (pinteraction=0.033). Similar associations were noted on gestational age 
(pinteraction=0.075). Amongst only IPTp-SP recipients, relative to women who last received SP >4 weeks 
before delivery, recent SP receipt was associated with lower birthweight in women with wildtype 
parasites (MD:118g, 95% CI:-376,139; p=0.361) and higher birthweight in women with A581G-
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Conclusions. The effectiveness on birthweight of IPTp-SP is compromised by A581G-bearing 
parasites, but there was no evidence that the adverse effects of these parasites are exacerbated by 
antenatal SP. 
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Nearly all malaria-endemic African countries provide intermittent preventive therapy to 
pregnant women (IPTp) with monthly sulfadoxine-pyrimethamine (SP) beginning in the 
second trimester. Antenatal receipt of SP reduces the risk of anemia, antenatal infections, 
placental infections, and low birth weight (LBW),[1], and its benefit on LBW is only partially 
attenuated [2] by widespread Plasmodium falciparum resistance to SP across Africa.[3, 4] 
Resistance to SP is conferred by mutations in the parasite genes dihydrofolate reductase 
(dhfr) and dihydropteroate synthase (dhps).[5] The rapid spread across Africa of dhfr 
mutations at codons 51, 59, and 108 rendered SP unsuitable for malaria case 
management.[6] In contrast, dhps mutations at codons 437, 540, and 581 have been slower 
to spread across African settings. In East Africa, where the A437G and K540E mutations are 
largely fixed, SP as IPTp has remained beneficial to protect from LBW.[2, 4]  
 
In recent years, the dhps A581G allele has been more commonly reported in East Africa, 
where it has been directly associated in pregnant women with increased placental parasite 
densities,[7] reduced birthweight,[8] and, in one study in northern Tanzania, with enhanced 
morbidity in women receiving SP.[9] In this observational study, the receipt of SP within 4 
weeks of delivery among women with placental malaria was associated with a higher density 
of placental parasites and a higher fraction of parasites bearing the A581G allele. Also, 
ecological studies[4, 10] of IPTp-SP use and LBW in areas of varying prevalence of A581G 
alleles suggest that high prevalences of these resistant parasites may undermine IPTp-SP 
efficacy as a strategy to improve birthweight.[4] Overall, however, associations between 
A581G-bearing parasites and SP efficacy have been inconsistent, and there exists an 
ongoing need to characterize better the effects of A581G alleles on delivery outcomes and 
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In this study, we investigated interactions between antenatal SP receipt, SP-resistant 
placental parasites, and delivery outcomes. We used parasites collected in a trial of 
pregnant Malawian women randomized to either standard IPTp-SP or to intermittent 
screening during pregnancy (ISTp) with a rapid diagnostic test (RDT) followed by treatment 
of RDT-positive infections with dihydroartemisinin-piperaquine (DP) 
(www.isrctn.com/ISRCTN69800930).[11] All three study sites had measurable frequencies of 
the dhps A581G allele in women at antenatal presentation (1-3.4%). Owing to the presence 
of this allele and a large population of SP-unexposed women, our study was uniquely able to 
analyze modifications of the effect of antenatal SP on delivery outcomes by resistant 
parasites. We hypothesized that parasites harboring the dhps A581G mutation in placental 
infections would be associated with higher parasite densities and worse birth outcomes and 
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Study cohort. We used specimens collected 2011-2014 from a randomized clinical trial in 
Malawi.[11] In this study, HIV-seronegative women presenting for antenatal care to three sites were 
randomized (1:1) to ISTp-DP or IPTp-SP and followed through delivery. Overall, the median number 
of scheduled ANC visits and SP doses was 4. As previously reported,[11] the prevalence of PCR-
positive infections was similar at baseline between ISTp-DP (44.4%) and IPTp-SP (43.0%) recipients, 
but higher in maternal or placental specimensat delivery in ISTp-DP recipients (30.1% v. 22.7%). 
Outcome assessments were as previously described for maternal, newborn, and placental 
measurements and molecular parasite detection.[12] For the latter, parasite densities were 
measured by reference to a standard curve on each reaction plate and expressed as ng/µL of strain 
3D7 genomic DNA.[13]  
Genotyping procedures. We used a two-stage genotyping approach: we first genotyped pools of 
parasites to identify those with non-fixed resistance alleles, and then we genotyped individual 
parasitemias within those pools with heterogeneous resistance alleles. For the first stage of pooled 
analyses, we defined 18 parasite populations on the basis of study arm (two), study site (three), and 
timing of specimen (antenatal booking, maternal peripheral blood at delivery, and placental blood) 
(Supplemental Table 1). The two largest populations (207 parasitemias each) were each divided into 
two, and therefore we created 20 pooled templates, each consisting of between 19 and 120 
parasitemias. For genotyping in the second stage, the same gDNA specimens were used as PCR 
templates, but in unpooled fashion. 
We amplified P. falciparum genes dhfr and dhps using nested PCR assays on pooled or individual 
gDNA templates.[14] Amplicons were prepared as barcoded sequencing libraries using the NEBNext 
Fast DNA Fragmentation and Library Prep Set for Ion Torrent (New England Biolabs, Ipswich, MA, 
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mixed in equimolar amounts by gene target and sequenced on an Ion Torrent PGM platform using 
318 chips.  
Sequence analyses. All dhfr and dhps reads were analyzed in Galaxy (usegalaxy.org):[15-17] reads 
were first aligned to 3D7 reference sequences for either dhfr (XM_001351443) or dhps (Z30654) 
using Bowtie2, and then variants at each position were quantified using MPileup. For quality filtering 
of allele frequencies, we allowed reads of any quality to be mapped to reference sequences but 
analyzed within those reads only bases with quality scores >q33 for dhfr or >q29 for dhps.[18] This 
enforces stringent quality while limiting false-discovery, resulting in expected per-base error 
probabilities of less than 5x10-4 (for dhfr) and 1.3x10-3 (for dhps). At resistance loci, the mutant allele 
frequency was defined as the proportion of reads at that locus that harbored the nucleotide 
substitution encoding the amino acid substitution conferring resistance; we censored frequencies in 
pooled parasitemias < 1% to mitigate the risk of false-discovery.[18] Read processing was performed 
by personnel masked to study data. 
Statistical analyses. We used Poisson regression using robust standard errors to compute Prevalence 
Ratios (PRs) on dichotomous outcomes and linear regression to compute mean differences on 
continuous outcomes and 95% confidence intervals (CIs) for each. Results are presented for crude 
models, for multivariable models, adjustment for treatment arm, gravidity, maternal underweight 
(body-mass index < 18.5 kg/m2), maternal bednet use the night before enrollment and conditioned 
on resistance allele using interaction terms. We estimated the significance of regression interaction 
terms between treatment arm and resistance allele using the Wald test. We performed sensitivity 
analyses of models on gestational age and birthweight by re-computing models after re-setting an 
outlier value for each variable to the lowest value of the 99th percentile of the remainder values. We 
used the Kruskal-Wallis test to compare parasite densities. A p-value of <0.05 was considered 
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Ethics. Written informed consent was obtained from all participants before enrollment. Ethical 
approval was obtained from the Malawian National Health Science Research Committee and 
the Liverpool School of Tropical Medicine; molecular testing of parasites was approved by 
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Frequencies of dhfr and dhps mutations in pooled parasite populations. Median (Interquartile 
Range [IQR]) read depth at loci of interest was 1,251 (427, 2583) for dhfr and 2,397 (1351, 
3781) for dhps (Figure 1A, 1B). Similar to parasites collected at antenatal booking,[11] 
across each study site, study arm, and specimen type, allele frequencies exceeded 92% for 
the dhfr substitutions N51I, C59R, and S108N, and 97% for the dhps substitutions A437G 
and K540E. (Supplemental Tables 2 & 3). We did not observe any pools harboring the dhfr 
I164L or the dhps I431V mutations. 
 
The frequency of the dhps A581G mutation ranged between 0 and 23% between the 20 
pools of parasites (Figure 1C) (antenatal booking: 0.6-6.5%, delivery: 0.1-2.5% in maternal 
peripheral parasites and 0-23.1% in placental parasites).  
 
Frequencies of dhfr and dhps mutations in individual placental parasitemias. We genotyped 
all individual placental parasites across dhfr and dhps loci from Mpemba, the study site with 
the highest frequency of dhps A581G alleles in placental parasites. At this site, the 
frequency of A581G alleles was similar at enrollment between IPTp-SP (4.3%) and ISTp-DP 
(3.1%) recipients. In placental samples, 144 women had PCR-detectable parasites (IPTp-
SP: 65, ISTp-DP: 79); after censoring samples with fewer than ten reads, we obtained allele 
frequencies for 121 and 125 parasitemias for loci in dhfr or dhps, respectively. Amongst 
women with placental infections, compared to those with genotype data, women missing 
genotype data did not differ significantly in randomization group or gravidity, but did have 
lower median placental parasite densities (0.14 x 10-3 ng/µL versus 0.02 x 10-3 ng/µL; 
p=0.0037 by Kruskal-Wallis). 
 
In 125 placental infections, mean (SD) frequencies were high for the dhfr substitutions N51I 
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I164L. Similarly, in 121 placental infections, mean (SD) frequencies were high for the dhps 
substitutions A437G (0.998 [0.01]) and K540E (0.999 [0.011]) and less than 0.001 for I431V. 
In contrast, the overall mean (SD) frequency of the A581G substitution was 0.037 (0.15) 
(Figure 1D), and the prevalence of the A581G mutation was 14.4% (18/125) among 
placental infections. Among these 18 placental infections, the median (IQR) allele frequency 
was 0.20 (0.001, 0.464). 
 
Associations of mutant alleles and clinical factors. Enrollment characteristics were similar in 
Mpemba between women who ultimately had placental infections with dhps A581G or 
wildtype parasites (Table 1). The prevalence of the A581G mutation in placental parasites 
was similar between women who had received IPTp-SP (9/58, 16%) and ISTp-DP (9/67, 
13%) (PR=0.87; 95% CI 0.34-2.18, p=0.760). Amongst women infected with placental 
parasites bearing the A581G allele (n=18), there was no evidence of differences in median 
(IQR) allele frequencies between those who had received IPTp-SP (0.002 [0.001-0.273] or 
ISTp-DP: (0.311 [0.001-0.464]; p=0.354 by Kruskal-Wallis). 
 
Effect of IPTp-SP vs. ISTp-DP by dhps581 alleles. Prior studies have suggested that 
A581G-bearing parasites modify the effect of antenatal SP to exacerbate placental 
morbidity.[9] We, therefore, tested among women with placental infection if the effects of the 
antenatal prevention strategy on delivery outcomes were modified by A581G-bearing 
placental parasites. Among these women in whom antenatal strategies failed to prevent 
placental malaria, compared to women allocated to ISTp-DP, receipt of IPTp-SP resulted in 
a non-significant 63g increase in birthweight (95% CI -87, 213; p=0.408) (Table 2). When 
conditioned on allele, IPTp-SP was associated with a 116g increase (95% CI -40, 272; 
p=0.142) in women with wildtype parasites and a 192g decrease (95% CI -648, 264; 
p=0.385) in women with A581G-bearing parasites (Figure 2) and this difference in effect 
was statistically significant (pinteraction=0.033). Furthermore, relative to ISTp-DP, IPTp-SP was 
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parasites (Mean Difference [MD]=0.64 weeks; 95% CI: 0.1, 1.2; p=0.032) but not among 
those infected with A581G-bearing parasites (MD=-0.44; 95% CI -2.7, 1.8; p=0.677) 
(pinteraction=0.075). We did not observe modification of the effect of antenatal SP receipt by 
allele on placental parasite density, placental inflammation, maternal hemoglobin 
concentration, or weight-for-age Z-score. (Table 2). 
 
Difference in outcomes by dhps581 alleles among SP recipients. Among the 55 women with 
placental infections who received IPTp-SP, the mean (SD) birthweight among 9 women 
infected with parasites carrying the A581G mutation were significantly lower than those 
among 46 women infected with wildtype parasites: 2606gr (596) vs. 3018g (418), MD=412gr 
(84, 740), p=0.015 (Table 2). This reflected a difference in gestational age (MD=1.24 weeks, 
-0.04, 2.52, p=0.057) rather than z-score for weight-for-gestational age (MD=0.30, -0.30, 
0.96, p=0.292) (Table 2). 
 
Timing of SP and outcome by dhps581 alleles. We next tested if SP receipt within four 
weeks prior to delivery modified the association of the A581G allele with birth outcomes 
(Table 3). The median (IQR) number of days since the last dose of SP prior to delivery was 
similar between women infected with wildtype (n=49, 20 [11, 33] days) and A581G-bearing 
parasites (n=9, 23 [14, 30] days; p=0.940 by Kruskal-Wallis). Overall, the timing of SP 
receipt did not modify the effect of SP on mean (SD) birthweight (SP≥28 days: n=20, 2941g 
[610] vs <28 days: n=35, 2956g [379], MD=15g, -252, 282, p=0.911). However, this differed 
significantly by 581 allele: recent SP receipt <28 days before delivery was associated with a 
783g increase in mean birthweight (95% CI -20, 1586, p=0.054) among the 9 women 
infected with A581G-bearing parasites and a 118gr decrease (-139, 375, p=0.361) among 
the 46 women infected with wildtype parasites (pinteraction=0.005) (Table 3, Figure 2). Similar 
effect modification by the timing of SP use and 581 allele was found for gestational age; 
recent SP intake was associated with longer duration of pregnancies (P=0.037) among 
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with wildtype parasites (p=0.590) (pinteraction=0.001). In addition, we did not observe 
associations between A581G-bearing parasites and significant increases in parasite density 
or intervillous inflammation with recent SP use (Table 3). Collectively, these findings suggest 
that recent SP use was not associated with increased morbidity among women carrying the 
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We investigated the impact of molecular SP resistance among P falciparum parasites on the 
effectiveness of IPTp-SP for antenatal malaria prevention in a large cohort of pregnant 
women in southern Malawi. Consistent with prior studies of antenatal malaria, parasites 
harboring the dhps A581G allele in placental infections were associated with reduced birth 
weight in IPTp-SP recipients relative to birthweights among IPTp-SP recipients infected with 
less resistant parasites; this observation was consistent with a similar association with a 
shorter gestational age. However, contrary to the previous trial in northern Tanzania 
suggesting SP use in the four weeks prior to delivery was associated with increased parasite 
densities and adverse pregnancy outcomes,[9] we found no such associations. Therefore, 
although failure of SP among women infected with parasites harboring the dhps A581G 
allele may manifest as placental infection with resistant parasites that are associated with 
worse birth outcomes, there was no evidence that recent SP use exacerbated malaria-
associated morbidity. 
 
Amongst recipients of SP with placental malaria, the presence of the dhps A581G allele was 
associated with a reduction in birthweight of 412g (Table 2). This association of the dhps 
A581G allele with reduced birthweight adds to the growing literature from antenatal 
studies,[8] delivery series,[7, 9] and ecological studies[4, 10] that parasites bearing the 
A581G allele partially undermine the improvements in birthweight following IPTp-SP. 
Notably, these associations were present despite the relatively low abundance of A581G 
alleles within placental infections: in 16 of the 18 women infected with A581G-bearing 
parasites, the A581G allele frequency within the placental infection was less than 50%, 
indicating minority variants within mixed populations (Figure 1D). Given the more frequent 
reporting of this mutation in the past decade,[3] these results further underscore the need to 
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Our study design, which included an SP-unexposed population, allowed us to investigate if 
the A581G allele modified the effect of SP use on birthweight among women with placental 
infections. Compared with SP-unexposed women in the ISTp arm, the effect of IPTp-SP on 
mean birthweight differed significantly between women infected with wildtype parasites (a 
116g increased relative to the ISTp arm) and those infected with A581G-bearing parasites (a 
192 decrease) (p=0.033) (Table 2). Additionally, we observed similar interactions between 
the allele and SP receipt on gestational age at delivery (interaction p=0.075). Although this 
agrees with a prior reported study,[19] these results were largely driven by a single outlier 
birth of a 1,250g viable infant at 30 weeks gestation to a mother who received only a single 
dose of SP; in a sensitivity analysis of these interactions in which this participant’s 
birthweight and gestational age were set to the lower limit of the 99th percentile of the overall 
distribution of each variable, these interactions remained but were not statistically significant 
(Supplemental Table 4). Taken together, these observations suggest that the lower 
birthweights observed in women infected with parasites harboring the A581G mutation in the 
SP recipients was driven by shorter gestation in these women rather than intrauterine growth 
retardation.  
 
We did not observe the previously-reported phenomenon whereby the receipt of SP in the 4 weeks 
prior to delivery exacerbated the pathology of A581G-bearing parasites (Table 3).[9] On the 
contrary, we found that recent SP use was associated with higher mean birthweight and longer 
gestation among women infected with parasites harboring the dhps A581G allele at delivery, and 
these findings were maintained in sensitivity analyses (Supplemental Table 5). In addition, there was 
no evidence that recent SP use modified the effect of SP on parasite density, intervillous 
inflammation, malaria pigment, or maternal hemoglobin concentrations (Table 3) in women 
harboring A581G-bearing parasites, each of which could provide a mechanism for the previously 
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SP use exacerbates the adverse effect of malaria infections in women infected with highly resistant 
parasites. 
 
Several other observations were notable. Firstly, other than the Mpemba site, we did not 
observe consistent increases from enrollment to delivery in the frequency of SP-resistance 
alleles. This is surprising, given the presence at baseline of parasites bearing the A581G 
mutation, the large mean number of SP doses received per woman (3.3) in the IPTp-SP 
group,  suboptimal efficacy of SP to clear parasites in Malawi,[2]  the high prevalence of 
“breakthrough” parasites at delivery, andreported selection during pregnancy for drug 
resistance mutations in dhfr by SP[20, 21] and pfmdr1 by mefloquine.[22] This lack of clear 
increase in A581G alleles may be the result of our ecological approach to genotyping, in 
which we compared pairings of allele frequencies between only 3 sites, or more mild 
selection on the A581G allele by sulfadoxine compared with that on dhfr alleles by 
pyrimethamine. Additionally, there was an absence of the dhfr I164L substitution, which 
confers a higher degree of pyrimethamine resistance and, for obscure reasons, has 
remained rare in African settings, as well as the lack of appearance of the dhps I431V 
substitution, which has been reported in West Africa in association with the A581G 
substitution,[23, 24] but is of uncertain clinical significance.  
 
Why did pooled genotyping fail to detect any A581G alleles in the Mpemba placental 
specimens from ISTp-DP recipients? (Figure 1C) When tested individually, we identified 
A581G-bearing parasites in 9/66 of these placental specimens. To explore this, for each 
parasitemia, we computed the product of the molecular parasite density and the proportion 
of wildtype and mutant allele at codon 581; we then summed these absolute allele densities 
for each parasitemia within the ISTp group and computed an estimated proportion of alleles. 
Using this approach, we estimated that parasites bearing the A581G allele comprised 8.62% 
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those parasites pooled from women who received ISTp. In prior applications,[18, 25] pooled 
amplification and sequencing has not been demonstrated to be sensitive to minority variants 
comprising below 1% of a mixed infection.  
 
Our study has several limitations. Common dhfr and dhps mutant alleles are nearly fixed in 
Malawi, and we were able to analyze the effect of SP resistance only as a function of A581G 
allele frequency and only in one study site. However, the epidemiology of SP resistance 
markers in Malawi is similar to that in other settings in East and Southern Africa, enhancing 
the generalizability of our findings in this part of Africa. As noted above, some subgroup 
analyses were limited by the very few women infected with the A581G allele and with the 
specified co-incident outcomes. Therefore we analyzed a range of delivery outcomes to 
assess for consistency between effects. Finally, errors in Ion Torrent sequencing could have 
biased results, particularly if error rates are associated with template abundance; to mitigate 
this known risk, we only interrogated known resistance loci and analyzed only high-quality 
base calls. 
 
Our results indicate that the effectiveness of IPTp with SP is compromised in women 
infected with A581G-bearing parasites. However, there was no evidence that SP use 
exacerbates the adverse effect of malaria infections in women infected with these resistant 
parasites. These findings, together with reports of the increased spread of this allele[3] and 
of its association in ecological studies with a loss of IPTp-SP efficacy to prevent LBW,[4] 
underscore the necessity to identify alternative strategies to IPTp-SP for the prevention of 
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Table 1. Maternal characteristics at antenatal enrollment among women in Mpemba with placental 
malaria by dhps codon 581 allele 
 









Allocated to IPTp-SP, % (n/N) 45.8 (49/107) 50 (9/18) 0.741 
Paucigravidae, %, (n/N) 67.3 (72/107) 83 (15/18) 0.171 
Maternal age, y, mean (SD) 21.9 (4.9) 20.9 (3.9) 0.413 
Gestational age at enrollment, days, mean 
(SD) 
146 (23) 147 (18) 0.872 
Maternal weight, kg, mean (SD) 54.0 (6.0) 53.1 (5.0)  
Maternal height, cm, mean (SD) 153.7 (5.9) 153.4 (5.9) 0.890 
Maternal BMI < 18.5 kg/m
2
, % (n/N) 1.9 (2/107) 0 0.559 
Used bednet last night, % (n/N) 4.7 (5/107) 6 (1/18) 0.871 




55.1 (59/107) 39 (7/19) 0.201 
a Computed either with the chi-squared test or the student’s t-test.  
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Table 2. Comparisons of clinical and parasitological variables among women with PCR-positive placental malaria parasites in Mpemba study site 
with and without the dhps A581G mutation by study arm 













No., mean (SD), g 
 
All infected women  121, 2916 (415) 66, 2887 (364) 55, 2950 (471) 63 (-87, 213) 0.408  
dhps A581  103, 2953 (399) 57, 2901 (379) 46, 3018 (418) 116 (-40, 272) 0.142  
dhps A581G  18, 2702 (454) 9, 2797 (248) 9, 2606 (596) -192 (-648, 264) 0.385  
Mean difference (95% CI) -252 (-457, -46) -104 (-365, 158) -412 (-740, -84)    
p-value
a
 0.017 0.432 0.015    
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Parasite density,  
No.,  median (IQR), ng/uL x 10-3 
 
All infected women  125, 0.14 (0.03, 2.5) 67, 0.27 (0.04, 4.1) 58, 0.10 (0.03, 0.7)  0.110  
dhps A581  107, 0.13 (0.02, 2.5) 58, 0.26 (0.04, 4.1) 49, 0.09 (0.03, 0.6)  0.086  
dhps A581G  18, 0.26 (0.03, 3.0) 9, 0.27 (0.05, 0.99) 9, 0.11 (0.04, 3.0)  0.895  
p-value
a
 0.288 0.269 0.672    
      0.306 
Intervillous inflammation leukocytes ≥ 5 
%, n/N 
All infected women 38 (47/124) 38 (25/66) 38 (22/58)  0.995  
dhps A581 40 (42/106) 40 (23/57) 39 (19/49)  0.869  
dhps A581G 28 (5/18) 22 (2/9) 33 (3/9)  0.599  
p-value
a
 0.338 0.297 0.757    
      0.769 
Maternal hemoglobin at delivery 
No.,mean (SD), g/dL 
 
All infected women  125, 12.1 (1.7) 67, 11.9 (1.8) 58, 12.2 (1.6) 0.3 (-0.4, 0.9) 0.432  
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dhps A581G  18, 12.5 (2.3) 9, 12.2 (2.2) 9, 12.8 (2.6) 0.6 (-1.8, 3.0) 0.610  
Mean difference (95% CI) 0.5 (-0.4, 1.4) 0.3 (-1.0, 1.6) 0.7 (-0.4, 1.9)    
p-value
a
 0.237 0.643 0.219    
      0.538 
Gestational age at delivery 
No.,mean (SD), weeks 
 
All infected women  122, 37.6 (1.6) 66, 37.3 (1.5) 56, 37.8 (1.8) 0.46 (-0.1, 1.0) 0.123  
dhps A581  104, 37.7 (1.5) 57, 37.4 (1.5) 47, 38.0 (1.4) 0.64 (0.1, 1.2) 0.032  
dhps A581G  18, 37 (2.2) 9, 37.2 (1.0) 9, 36.8 (3.0) -0.44 (-2.7, 1.8) 0.677  
Mean difference (95% CI) -0.67 (-1.5, 0.2) -0.16 (-1.2, 0.9) -1.24 (-2.5, 0.04)    
p-value
a
 0.106 0.756 0.057    
      0.075 
Weight-for-age Z-score 
No., mean (SD) 
 
All infected women  121, 0.26 (0.87) 66, 0.23 (0.88) 55, 0.30 (0.86) 0.07 (-0.24, 0.39) 0.650  
dhps A581  103, 0.31 (0.90) 57, 0.28 (0.93) 46, 0.36 (0.87) 0.08 (-0.28, 0.43) 0.674  
dhps A581G  18, -0.04 (0.66) 9, -0.10 (0.45) 9, 0.02 (0.85) 0.12 (-0.56, 0.80) 0.706  
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 0.113 0.232 0.292    
      0.427 
 
CI: confidence interval; SD: standard deviation; g: grams; dL: deciliter; IQR: interquartile range; ISTp-DP: Intermittent screening during pregnancy 
and treatment with dihydroartemisinin-piperaquine; IPTp-SP: Intermittent preventive therapy during pregnancy with sulfadoxine-
pyrimethamine. 
a Computed by linear regression or the Kruskall-Wallis test (for continuous variables) or the chi-squared test (for categorical variables). 
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Table 3. Effect of dhps A581G mutation on the impact of recent SP on birth outcomes among women receiving IPTp-SP  
 All women SP ≥ 28 days 
before delivery 











No., mean (SD), g 
 
Overall 55, 2950 (471) 20, 2941 (610) 35, 2956 (379) 15 (-252, 282) 0.911  
dhps A581 46, 3018 (418) 17, 3092 (463)  29, 2974 (390) -118 (-375, 139) 0.361  
dhps A581G 9, 2606 (596) 3, 2083 (722) 6, 2867 (339) 783 (-20, 1586) 0.054  
Mean difference (95% CI) -412 (-740, -84) -1009 (-1665, -353) -107 (-457, 242)    
p-value
a
 0.015 0.005 0.536    
      0.005 
Parasite density 




Overall 58, 0.10 (0.03, 0.70) 22, 0.09 (0.03, 3.4) 36, 0.10 (0.03, 0.53)  0.737  
dhps A581 49, 0.09 (0.03, 0.60) 19, 0.11 (0.02, 3.4) 30, 0.08 (0.03, 0.31)  0.594  
dhps A581G 9, 0.11 (0.04, 3.0) 3, 0.04 (0.03, 125) 6, 1.10 (0.04, 3.0)  0.796  
p-value
a
 0.269 0.811 0.188    
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Intervillous inflammation leukocytes ≥ 5 
%, n/N 
Overall 38 (22/58) 36 (8/22) 39 (14/36)  0.847  
dhps A581 39 (19/49) 42 (8/19) 37 (11/30)  0.703  
dhps A581G 33 (3/9) 0 (0/3) 50 (3/6)  0.134  
p-value
a
 0.757 0.159 0.541    
      0.811 
Maternal hemoglobin at delivery 
No.,mean (SD), g/dL 
 
Overall 58, 12.2 (1.6) 22, 12.1 (1.4) 36, 12.8 (2.6) 0.35 (-0.53, 1.2) 0.427  
dhps A581 49, 12.1 (1.4) 19, 12.0 (1.1) 30, 12.1 (1.5) 0.08 (-0.73, 0.89) 0.836  
dhps A581G 9, 12.8 (2.6) 3, 11.6 (0.9) 6, 13.4 (3.1) 1.75 (-2.7, 6.2) 0.379  
Mean difference (95% CI) 0.72 (-0.44, 1.9) -0.39 (-1.8, 0.99) 1.3 (-0.40, 2.9)    
p-value
a
 0.219 0.560 0.130    
      0.273 
Gestational age at delivery 
No., mean (SD), weeks 
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dhps A581 47, 38.0 (1.4) 18, 38.2 (1.5) 29, 37.9 (1.4) 0.24 (-1.1, 0.64) 0.590  
dhps A581G 9, 36.8 (3.0) 3, 34.0 (3.5) 6, 38.2 (1.6) 4.2 (0.33, 8.0) 0.037  
Mean difference (95% CI) -1.2 (-2.5, 0.04) -4.2 (-6.6, -1.8) 0.24 (-1.1, 1.5)    
p-value
a
 0.057 0.002 0.714    
      0.001 
Weight-for-age Z-score 
No., mean (SD) 
 
Overall  55, 0.30 (0.9) 20, 0.31 (0.9) 35, 0.30 (0.8) -0.01 (-0.50, 0.48) 0.967  
dhps A581 46, 0.36 (0.9) 17, 0.47 (0.8) 29, 0.29 (0.9) -0.18 (-0.72, 0.35) 0.495  
dhps A581G 9, 0.02 (0.8) 3, -0.62 (1.2) 6, 0.34 (0.4) 0.96 (-0.28, 2.2) 0.109  
Mean difference (95% CI) -0.33 (-0.96, 0.30) -1.1 (-2.3, 0.07) 0.05 (-0.71, 0.82)    
p-value
a
 0.292 0.064 0.886    
      0.254 
 CI: confidence interval; SD: standard deviation; g: grams; dL: deciliter; IQR: interquartile range; SP: sulfadoxine-pyrimethamine. 
a Computed by linear regression or the Kruskall-Wallis test (for continuous variables) or the chi-squared test (for categorical variables). 
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Figure 1. Frequencies of P. falciparum dhps A581G alleles in pooled (A) and individual placental (B) 
parasite templates.  
A. Frequencies of dhps A581G allele in pooled parasitemias, by study site, study arm, and specimen type. 
* The sequencing of pooled maternal peripheral parasites from Chikwawa IPTp-SP recipients failed to 
yield analyzable reads. 
B. Frequency distribution within individual placental parasitemias of dhps A581G alleles in participants 
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Figure 2. Comparisons of continuous delivery outcomes among women with PCR-positive placental malaria parasites with and 
without the dhps A581G mutation by study arm and, among SP recipients, by timing of most recent SP dose 
 
White boxes: dhps A581; Dark gray boxes: dhps A581G. Thick line within each plot indicates median, dotted lines are quartiles. Overlying dots 
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